Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;6(Suppl 1):3-6.

Newer antidepressants in the primary care setting

J Sloan Manning  1
Affiliations

Newer antidepressants in the primary care setting

J Sloan Manning. Prim Care Companion J Clin Psychiatry. 2004.

Abstract

Because major depression has negative effects on other disease states, proper recognition and treatment of depression are important in the primary care setting. Although the perfect antidepressant does not yet exist, newer antidepressants have advanced the field. This article will summarize key features of 3 newer antidepressants that represent advances in psychopharmacology: mirtazapine, which has a dual effect on serotonergic and noradrenergic systems; escitalopram, the latest selective serotonin reuptake inhibitor, which is the first pure antidepressant stereoisomer in clinical use; and duloxetine, a dual reuptake inhibitor of norepinephrine and serotonin that is expected to be clinically available in the near future.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Change in Mean 17-Item Hamilton Rating Scale for Depression (HAM-D-17) Total Score During Treatment (intent-to-treat sample)a
Figure 2.
Figure 2.
Mean Change From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) in Depressed Patients Treated With Escitalopram (10 or 20 mg/day), Citalopram, or Placeboa
Figure 3.
Figure 3.
Effect of Placebo (N = 68), Duloxetine (N = 66), and Fluoxetine (N = 33) on 17-item Hamilton Rating Scale for Depression Total Scores (least-squares mean change from baseline) During the 8-Week Treatmenta
Figure 4.
Figure 4.
Effect of Placebo and Duloxetine 60 mg/day on Visual Analog Scale Measure of Overall Pain Severitya
See this image and copyright information in PMC

References

    1. Baldwin DS. Monoamine systems in depression: towards better understanding of the disorder and improved treatment options. Hum Psychopharmacol. 1998;13:293–295.
    1. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol. 1995;10:25–35. - PubMed
    1. van Moffaert M, de Wilde J, and Vereecken A. et al. Mirtazapine is more effective than trazodone: a double-blind multicentre trial in hospitalized depressed patients. Int Clin Psychopharmacol. 1995 10:3–9. - PubMed
    1. Marttila M, Jaaskelainen J, and Jarvi R. et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol. 1995 5:441–446. - PubMed
    1. Leinonen E, Skarstein J, and Behnke K. et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol. 1999 14:329–337. - PubMed